Skip to main content
. Author manuscript; available in PMC: 2021 Mar 23.
Published in final edited form as: Ann Oncol. 2020 Sep 3;31(11):1506–1517. doi: 10.1016/j.annonc.2020.08.2232

Figure 2. Recommended algorithm for NTRK gene fusion testing in sarcomas.

Figure 2.

GIST, gastrointestinal stromal tumor; IFS, infantile fibrosarcoma; IHC, immunohistochemistry; IMT, inflammatory myofibroblastic tumor; LPS, liposarcoma; MPS, massive parallel sequencing; NTRK, neurotrophic tyrosine receptor kinase; RT-PCR, reverse transcription polymerase chain reaction; TRK, tropomyosin receptor kinase.

a For patients at high risk of relapse, NTRK gene fusion testing might provide clinically actionable information for later in the disease course.

b If histology is typical then confirmation by MPS is recommended.

c Treatment may be considered concurrently with confirmatory MPS.

d Consider parallel validation by MPS or RT-PCR to confirm that fusion is in-frame.

e Avoid IHC screening in cases with myogenic and neural differentiation due to the high rate of false positivity.